Clinical Rheumatology

, Volume 33, Issue 9, pp 1197–1207 | Cite as

Key facts and hot spots on tumor necrosis factor receptor‐associated periodic syndrome

  • Donato Rigante
  • Giuseppe Lopalco
  • Antonio Vitale
  • Orso Maria Lucherini
  • Caterina De Clemente
  • Francesco Caso
  • Giacomo Emmi
  • Luisa Costa
  • Elena Silvestri
  • Laura Andreozzi
  • Florenzo Iannone
  • Mauro Galeazzi
  • Luca Cantarini
Review Article


Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), formerly known as familial Hibernian fever, is the most common autosomal dominant autoinflammatory disease, resulting from mutations in the TNFRSF1A gene, encoding the 55-kD tumor necrosis factor receptor. The pathophysiologic mechanism of TRAPS remains ambiguous and only partially explained. The onset age of the syndrome is variable and the clinical scenery is characterized by recurrent episodes of high-grade fever that typically lasts 1–3 weeks, associated with migrating myalgia, pseudocellulitis, diffuse abdominal pain, appendicitis-like findings, ocular inflammatory signs, and risk of long-term amyloidosis. Fever episodes are responsive to high-dose corticosteroids, but different classes of drugs have been reported to be ineffective. The use of etanercept is unable to control systemic inflammation, while interleukin-1 blockade has been shown as effective in the control of disease activity in many patients reported so far.


Autoinflammatory disease Interleukin-1 inhibitors Tumor necrosis factor receptor‐associated periodic syndrome 


An impaired control of innate immune cells leading to unprovoked attacks of systemic inflammation in the absence of autoantibodies and autoreactive T cells is the common platform of autoinflammatory diseases (AIDs), a heterogeneous group of clinical entities, so-called as they were to be differentiated from autoimmune diseases, that are conversely caused by dysregulation of the adaptive immune system [1, 2]. The unifying pathogenetic mechanism of AIDs is represented by abnormal signaling in interleukin (IL)-1 pathways and tumor necrosis factor (TNF)-α, leading to delayed turning off of the normal inflammatory response [3]. Schematically, AIDs can be distinguished in monogenic hereditary disorders (briefly listed in the Table 1) and multifactorial polygenic disorders, the latter including Behçet’s syndrome, Still’s disease, systemic juvenile idiopathic arthritis, recurrent pericarditis, and periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome, best known as PFAPA syndrome [4]. In simple words, monogenic AIDs are characterized by a prototypical scenery consisting of recurrent episodes of fever and variables signs of systemic inflammation, usually starting in the pediatric age [5, 6]. Their diagnostic identification derives from the combination of clinical and biohumoral data, eventually corroborated by genetic investigations.
Table 1

Brief summary of the hereditary autoinflammatory diseases


Gene locus



Clinical features



MEFV 16p13.3



Fever, serositis, arthralgias or arthritides, erysipelas-like

eruption on the legs, response to colchicine prophylaxis,

amyloidosis in untreated or noncompliant patients

Colchicine, anakinra, canakinumab


TNFRSF1A 12p13

p55 tumor necrosis factor receptor type-1


Fever, severe migrating muscle and joint involvement,

conjunctivitis, periorbital edema, arthralgias or arthritis,

serosal involvement, steroid responsiveness of febrile attacks,

risk of amyloidosis

Corticosteroids, etanercept, anakinra,

canakinumab, tocilizumab


MVK 12q24

Mevalonate kinase


Fever, widespread polymorphous rash, arthralgias, abdominal

pain, diarrhea, lymph node enlargement, oral aphthosis

NSAIDs, anakinra, corticosteroids






Fever, cold-induced urticaria-like rash, conjunctivitis,


Anakinra, canakinumab, rilonacept


Fever, urticaria-like rash, conjunctivitis, arthralgias,

neurosensorial deafness, risk of amyloidosis


Fever, urticaria-like rash, uveitis, papilledema, deforming

arthritis involving large joints, neurosensorial deafness, aseptic

chronic meningopathy, risk of amyloidosis






Pauciarticular pyogenic arthritis, osteo-cartilaginous erosions of joints, cystic acne, pyogenic abscesses

Infliximab, anakinra




Lipin 2


Recurrent multifocal osteomyelitis, congenital dyserythropoietic anemia, chronic dermatosis resembling Sweet’s syndrome

NSAIDs, corticosteroids, anakinra, canakinumab




Nod2 (Card15)


Intermittent fevers, granulomatous dermatitis with

ichthyosis-like changes, symmetrical granulomatous

polyarthritis, recurrent severe granulomatous panuveitis

Corticosteroids, immunosuppressive agents,

anti-TNF-α drugs, anakinra

AD autosomal dominant, AR autosomal recessive, BS, Blau syndrome, CINCAs, chronic inflammatory neurological cutaneous articular syndrome, FCAS familial cold autoinflammatory syndrome, FMF familial Mediterranean fever, MAJEEDs Majeed syndrome, MKD mevalonate kinase deficiency syndrome, MWS Muckle–Wells syndrome, NSAIDs non-steroidal antinflammatory drugs, PAPAs pyogenic arthritis, pyoderma gangrenosum, acne syndrome, TRAPS tumor necrosis factor receptor-associated periodic syndrome

Tumor necrosis factor receptor‐associated periodic syndrome (TRAPS, MIM #142680) is the most frequent autosomal dominant autoinflammatory disorder [7], caused by mutations in the TNFRSF1A gene, encoding the 55-kD type-1 receptor of TNF-α (also cited as TNFRSF1A) [8]. Clinically speaking, TRAPS is characterized by recurrent long-lasting fever attacks variously accompanied by abdominal and/or chest pain, migratory rash and myalgia, periorbital edema, and joint and ocular symptoms [9, 10]. Serous membrane inflammation, usually in the form of polyserositis, can also occur [11, 12, 13, 14, 15]. TRAPS prevalence has not been well established, but its incidence among German children has been calculated as 5.6 per 107 person/year [16].

The genetic basis of TRAPS

TRAPS was first described in 1982 as familial Hibernian fever, reflecting the Irish/Scottish ancestry of patients in the very first reports [7], and was then found to be prevalent in patients of northern European ancestry [8, 17]. However, families of other ethnic groups such as Jewish, Arab, Puerto-Rican, and Asiatic suffering from TRAPS have also been reported [18]. Genetic mutations associated with TRAPS have been detected on locus 12p13, a chromosome region including the gene TNFRSF1A [19, 20]. At present, 138 TNFRSF1A sequence variants have been associated with TRAPS []. Gene mutations result in a subverted TNFRSF1A three-dimensional shape and are mainly located on exons 2, 3, 4, and 6. Moreover, they are mostly single-nucleotide missense mutations (about 94 %) and involve the first two N-terminal cysteine-rich domains CRD1 and CRD2, which are fundamental for the receptor’s three-dimensional structure. In addition, the C98Y and F112I mutations in the domain CRD3, the I170N mutation in close proximity to the transmembrane region of the TNF receptor (exon 6) together with three deletions and one deletion/insertion affecting the extracellular domain have also been reported [21]. Variants involving cysteine residues are associated with a more severe disease phenotype and a higher risk to develop amyloidosis [10]. Other mutations can affect the secondary structure of the receptor, such as those introducing or removing proline residues (P46L, L67P, S86P, R92P), or affecting residues involved in hydrogen bonds between different loops of the protein (T50M, I170N) [22]. The R92Q and P46L variants are considered as non-structural low-penetrance mutations, while the D12E, V95M, and R104Q variants have been described in patients with mild or atypical manifestations [23, 24].

Pathogenetic studies related to TRAPS

The TNF-α and TNF receptor superfamilies play a key role in triggering inflammation, both locally and systemically [25]. TNF-α is a type II transmembrane protein, known to mediate a variety of biological processes including apoptosis, cell proliferation, immune modulation, autoimmune diseases, and other pathological conditions [26, 27, 28, 29, 30, 31]. Although monocytes and macrophages are the main resources of TNF, mast cells, T and B lymphocytes, natural killer cells, neutrophils, endothelial cells, smooth and cardiac muscle cells, fibroblasts, and osteoclasts might be involved in its synthesis [32, 33, 34]. All known TNF functions result by the binding to one of two distinct receptors, designated TNFR1 (best known as TNFRSF1A, CD120a, p55) and TNFR2 (also known as TNFRSF1B, CD120b, p75), which promote different signaling pathways leading to the activation of transcription factors, such as NF-κB, c-Jun/activator protein 1 (AP-1), and mitogen activated protein kinases (MAPKs) [35]. TNFR1 is a transmembrane protein consisting of an extracellular domain constituted by four tandem repeat cysteine-rich domains (CRD1–4), a transmembrane region, and an intracellular death domain (DD) [36]. The N-terminal cysteine-rich domain CRD1, also called pre-ligand assembly domain (PLAD), mediates homotypic receptor interactions and allows ligand binding and signal transduction [37]. The extracellular domain is characterized by the presence of intramolecular disulfide bridges, which constitute the binding site for TNF-α and also permits the self-assembly of the protein.

The TNF-α binding to TNFR1 induces receptor trimerization, which then allows its intracellular DD and TNFR-associated death domain protein (TRADD) to interact: this interaction recruits various adapter molecules, crucial for cell survival, inflammatory signals, and apoptosis. Indeed, it is known that a macromolecular platform, involving TNF receptor-associate factor (TRAF) and receptor-interacting protein (RIP) proteins, is recruited via the adapter TRADD to the plasma membrane that in turn activates I kappa B kinase (IKK) pathway, leading to NF-κB-mediated cytokine production as well as production of the cellular FLICE-like inhibitory protein (c-FLIP), a procaspase 8-like regulator of death ligand-induced apoptosis, and Fas-associated death domain (FADD), also involved in the fate decisions of different inflammatory cells [35]. Figure 1 gives a simplified representation of the TNFR1 signaling.
Fig. 1

Schematic representation of tumor necrosis factor-receptor (TNFRSF1A) signaling: binding of the TNF-α trimer to the extracellular domain of TNFRSF1A leads to the interaction between TNFRSF1A intracellular death domain (DD) and TNFR-associated death domain (TRADD); TRADD recruits the adaptor proteins TNF receptor associate factor (TRAF) and receptor-interacting protein (RIP) that initiate signaling cascades leading to nuclear translocation of the NF-κB and its activation to promote cell survival and inflammatory signals. Additional TRADD-mediated recruitment of Fas‐associated death domain (FADD) results in the activation of caspase 8, which after various passages leads to apoptosis. Abbreviations: death domain (DD); cysteine-rich extracellular domains (CRDs)

Furthermore, after activation, TNFRSF1A undergoes metalloprotease-mediated cleavage of its extracellular domain by the transmembrane glycoprotein ADAM17 (also called TNF-α converting enzyme or TACE), releasing soluble TNFR1 into the bloodstream, where it binds circulating free TNF-α and contributes to stop inflammation [21]. In recent years, TRAPS understanding has rapidly expanded, also due to the discovery of a progressively increasing number of TNFRSF1A mutations with several pathogenetic hypotheses proposed to explain disease mechanism [38].

Initially, it was hypothesized that TRAPS patients expressed a constitutively active or hypersensitive TNFRSF1A, resulting in overactivation of NF-κB and increased production of proinflammatory cytokines. However, transfection studies have found that both mutant and wild-type TNFR1 activate NF-κB equally [39]. Later, the “shedding hypothesis” suggested that structural mutations, including C33Y, T50M, C52F, and C88R, could lead to conformational changes of the protein, resulting in functional alteration and impaired cleavage of membrane-bound TNFR1, which in turn resulted in loss of self-controlled inflammation. However, some TRAPS patients exhibit normal TNFR1 shedding [40], and TNF-α blockade by means of the soluble p75 TNF receptor-Fc fusion protein etanercept is not constantly effective in reducing TRAPS symptoms [41, 42].

Molecular modeling experiments have also suggested that some TNFRSF1A mutations, in particular those causing abnormal intramolecular disulfide bonds, are linked with a defect in the sorting of TNFRSF1A, suggesting the “TNF receptor trafficking dysfunction” hypothesis [39]. The abnormal oligomerization or misfolding of TNF receptors will result in a retention in the endoplasmic reticulum, leading to decreased binding to TNF and a reduction in TNF-induced apoptosis. As a consequence, enhanced sensitivity to innate immune stimuli and exaggerated autocrine production of inflammatory cytokines occur [43, 44]. In this regard, Balua et al. [45] and Kamata et al. [46] have demonstrated that peripheral blood leukocytes from TRAPS patients exhibit increased production of reactive oxygen species (ROS), which in turn potentiate MAPK signaling and release of inflammatory mediators. These data suggested that mutant TNFR1 expression leads to an increase in ROS production, resulting in the upregulation of proinflammatory cytokines such as IL-1β, TNF-α, and IL-6. Recently, interesting studies were carried out in order to investigate the link between endoplasmic reticulum and enhanced ROS production, following intracellular retention of mutant TNFR1 [47]. It is known that accumulation of unfolded or misfolded proteins in the endoplasmic reticulum results in a cellular stress response, defined “unfolded protein response” (UPR), aimed at restoring normal cell function by halting protein translation and transduction [48]. When cell functional recovery is not achieved, the UPR turns towards apoptosis [49]. On this basis, Dickie et al. have suggested that an URP-associated protein, called spliced-X-box binding protein-1 (sXBP1), might be involved in the pathogenesis of TRAPS [47, 38]. In fact, lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells from TRAPS patients demonstrated increased sXBP1 levels in comparison with healthy controls. Notably, sXBP1 levels were reduced (up to 40 %) after antioxidant administration, suggesting an association between oxidative stress, due to retention of mutated TNFR1 in the endoplasmic reticulum and increased LPS-induced levels of ROS through XBP1 pathway. Therefore, it is conceivable to assume that accumulation of mutant TNFR1 results in endoplasmic reticulum stress and XBP1 splicing, but not a full classical UPR [47].

Interestingly, recent studies have also showed that autophagy, involved in the degradation of dysfunctional intracellular organelles, cell membranes, and proteins, might contribute to inflammation in patients with TRAPS. In particular, Bachetti et al. discovered that defective autophagy showed in TRAPS cells is associated with enhanced NF-κB activation as well as IL-1β hypersecretion and chronic inflammation [50]. Figure 2 schematically depicts this newly proposed mechanism involved in the pathogenesis of febrile attacks in TRAPS.
Fig. 2

Newly proposed mechanisms involved in the pathogenesis of febrile attacks in tumor necrosis factor receptor-associated periodic syndrome: the intracellular accumulation of the mutant TNFRSF1A (mtTNFRSF1A, to differentiate by the wild-type receptor, named wtTNFRSF1A) in the endoplasmic reticulum (ER) leads to enhanced sensitivity to innate immune stimuli, such as lipopolysaccharide (LPS), and induces an exaggerated autocrine production of inflammatory cytokines by means of MAPK (mitogen activated protein kinase) activation. This situation is due to altered mitochondrial (MT) function, which results in increased production of reactive oxygen species (ROS), potentiating MAPK signaling itself. In addition, recent data demonstrate that a defective autophagy due to the accumulation of mtTNFRSF1A is also associated with enhanced NF-κB activity, subsequent secretion of proinflammatory cytokines and chronic inflammation. Abbreviations: Toll-like receptor 4 (TLR4)

In the last years, several evidences have suggested that microRNAs (miRNAs), small non-coding RNAs (18–25 nucleotides in length) that can regulate every aspect of cellular activity, from differentiation and proliferation to apoptosis, have a central role in many immune processes and in rheumatologic diseases [51, 52]. In this regard, Lucherini et al. have evaluated circulating miRNAs levels in TRAPS patients, correlating these results with parameters of disease activity and/or disease severity [53]. TRAPS miRNA expression profile revealed a signature of six miRNAs specific for TRAPS, all significantly down-regulated in TRAPS patients in comparison with healthy controls. Interestingly, four miRNAs were found differently expressed between patients treated with anakinra versus untreated ones. In particular, miR-92a-3p and miR-150-3p expression was significantly decreased in untreated patients, while their expression was similar to controls in samples obtained during anakinra treatment. In addition, MiR-92b levels were inversely correlated with the number of febrile attacks per year, while miR-377-5p levels were positively correlated with serum amyloid-A (SAA), a relevant marker of disease activity in AIDs, suggesting that miRNA levels may be helpful in evaluating the response to treatment [53].

Finally, Rittore et al. have investigated about a further mechanism of TNFRSF1A regulation, founding that three polymorphisms in the promoter, resulting in an exon 2-spliced transcript-TNFR1-d2, may affect clinical features of TRAPS by means of a dual mechanism involving transcription and splicing [54].

TRAPS clinical features

TRAPS presents a significant heterogeneity of clinical features, probably due to the broad spectrum of TNFRSF1A mutations [36]. The average age at disease onset is around 3 years; however, adult onset up to the sixth decade has been described as well [55, 56]. Usually fever attacks occur every 5–6 weeks, and their mean length is around 14 days, even if their duration may last many weeks [57]. Patients with adult-onset TRAPS may also display a clinical picture mimicking familial Mediterranean fever, also in the duration of inflammatory attacks (only 1–3 days) [58]. Typical TRAPS attacks often begin with muscle cramps, followed by fever associated with skin manifestations, arthritis, abdominal, and/or chest pain [59, 60, 61]. Serous membrane inflammation is commonly observed, usually in the form of polyserositis [11, 12, 13, 14, 15, 62]. Respiratory, genitourinary, and lymph node involvement can also occur [9, 10, 57]. Fever attacks recur either spontaneously or after minor triggers such as local injury, minor infection, variable stress, exercise, and hormonal changes. Cutaneous manifestations occur in 84 % of cases [63], mainly in the form of centrifugal migrant erythema. Edematous plaques, urticarial patches, and even erysipelas-like lesions represent other potential skin manifestations, histologically characterized by dermal perivascular lympho-monocytic infiltrate. These lesions are painful and warm to the touch and may predominate in the upper chest or lower limbs. Early signs consist of erythematous macules and papules in groups or isolated, and are characterized by a migratory pattern, classically centrifugal, expanding towards the periphery in large plaques in the course of days [64]. Annular and serpiginous patches can also occur [7, 65]. Myalgia is typically migratory and associated with an overlying tender erythematous skin rash. Hull et al. showed that myalgia corresponded with edema in the muscle compartment and histologically with monocytic fasciitis [66]. Arthralgia is more common than arthritis, which can usually occur as asymmetrical non-erosive oligo-monoarthritis, with predilection for large joints and mainly involving the knees, shoulders, elbows, hips, temporo-mandibular joints, and wrists. Sacroiliitis has also been reported [15]. Periorbital edema is a pathognomonic clinical manifestation [67] and is often associated with ocular pain, conjunctivitis, or uveitis [10]. Abdominal pain originating from inflammation of peritoneal serous membrane and/or abdominal wall muscles is another common TRAPS feature [11]; about one third of TRAPS patients experience laparotomy and appendectomy because of sterile acute peritonitis [68]. With regard to genitourinary system, a long-lasting inflammation can result in ureteral strictures [69]. Furthermore, scrotal pain due to tunica vaginalis testis involvement and neurological symptoms such as headache, aseptic meningitis, optic neuritis, and behavioral abnormalities represent other rarely reported features [70, 71].

Reactive amyloidosis is the most serious long-term complication of TRAPS, often leading to nephrotic syndrome or renal failure. Notably, patients carrying cysteine-involving TNFRSF1 mutations seem characterized by early disease onset and severe clinical manifestations, including reactive amyloidosis [72, 73]. On the contrary, low-penetrance mutations, such as R92Q, P46L, and T61I, are associated with a milder disease course, sometimes resembling a PFAPA-like phenotype, a later disease onset, and a lower risk of developing amyloidosis (2 versus 25 % of patients carrying high-penetrance TNFRSF1A variants) [74, 75]. Autonomic nervous system may also be involved by amyloidosis, giving rise to orthostatic hypotension and abnormal bowel habit [72]. Patients often display chest pain caused by pericarditis, pleurisy, or intercostal muscle pain. Recurrent pericarditis is common in low-penetrance mutated patients and sometimes represent the only clinical manifestation, mimicking autoimmune disorders with pericardial disease [57, 76, 77, 78, 79]. Interestingly, a recent analysis of TRAPS phenotypes has found a higher rate of pericarditis in patients carrying low-penetrance variants, in comparison with patients carrying a structural mutation. According to the same analysis, low-penetrance mutated patients were less frequently associated with a chronic disease course in comparison with high-penetrance mutated ones [23]. In addition, low-penetrance TNFRSF1A mutations were observed in about 6 % of unselected patients affected with idiopathic recurrent pericarditis (IRAP). For this reason, TRAPS mutations should be evaluated in patients with IRAP, specifically if they have a positive family history for pericarditis or periodic fever syndromes, poor response to colchicine, high number of recurrences, as well as the need for immunosuppressive agents [12, 13, 14, 78, 79, 80].

TRAPS may also be associated with acute myocarditis, a possible cause of sudden death from ventricular fibrillation, and restrictive cardiomyopathy, due to reactive amyloidosis [81, 82]. Notably, the non-cysteine mutation V173D has been related to cardiovascular manifestations, such as myocardial infarction and arterial thrombosis [42]. In this regard, the prolonged inflammatory state characterizing TRAPS may be the cause of endothelial dysfunction and a contributing factor to atherosclerosis [83]. Table 2 briefly shows the main most frequent TRAPS clinical features per organ involved.
Table 2

Main clinical manifestations of tumor necrosis factor receptor-associated periodic syndrome

Organ system

Common and less common clinical features


Centrifugal migratory erythema, edematous plaques, annular and serpiginous patches, urticarioid lesions


Muscle cramps, migratory myalgia, fasciitis, arthralgias, oligo-monoarthritis, sacroiliitis

Central nervous

Headache, aseptic meningitis, optic neuritis, behavioral abnormalities


Periorbital edema, conjunctivitis, ocular pain, uveitis


Peritonitis-like picture, abdominal pain, vomiting


Ureteral strictures, scrotal pain


Chest pain, pleurisy

Autonomic nervous

Orthostatic hypotension, bowel disturbance


Pericarditis, myocarditis, ventricular tachycardia, restrictive cardiomyopathy, risk of myocardial infarction and arterial thrombosis


Swollen and painful lymph nodes


Amyloidosis-related nephrotic syndrome

The identification of a mutation in the TNFRSF1A gene is needed for a definite diagnosis of TRAPS. In order to improve genetic diagnosis in adults suspected to have AIDs, Cantarini et al. have identified some variables strongly related to the probability of detecting mutations in the TNFRSF1A gene and also in the MEFV gene (which is responsible for familial Mediterranean fever). In addition, they developed, validated, and revised a diagnostic score for identifying patients at high risk to carry these mutations according to clinical manifestations, age of disease onset, and family history [55, 84, 85]. However, before this score can be recommended for widespread application, further evaluation by means of longitudinal studies on populations from different geographical areas is required.

Laboratory investigations in TRAPS

During inflammatory attacks, laboratory examinations show an increase of all inflammatory markers (erythro-sedimentation rate, C-reactive protein, fibrinogen, and haptoglobin), which usually drop to normal rates during symptom-free periods. Some patients may present neutrophil leukocytosis, thrombocytosis, hypo- or normochromic anemia, and a polyclonal gammopathy, due to stimulation of immunoglobulin synthesis by the numerous proinflammatory cytokines produced [86]. Another interesting laboratory parameter is the detection of low serum level of the soluble TNF receptor (<1 ng/ml) during the quiescent phase of the disease, resulting from a defective release of the receptor itself by cell membranes [9]. SAA is the acute-phase protein synthesized in the liver under stimulation by proinflammatory cytokines, which is significantly increased during inflammatory flares [87]: its amino-terminal fragment may deposit in various organs in the form of amyloid fibrils and lead to

the development of AA-amyloidosis. Measurement of circulating SAA levels is useful for monitoring disease activity and response to therapy, disclosing minimal subclinical inflammation even in the absence of symptoms. Therefore, the occurrence of proteinuria (>0.5 g/day) and increased SAA levels (>10 mg/l) should be taken into account to early suspect and detect amyloidosis [72].

The calcium-binding protein S100A12 (calgranulin C) has been proposed to be involved in specific calcium-dependent signal transduction pathways, and its regulatory effect on cytoskeletal components may modulate various neutrophil activities, leading to enhanced inflammatory responses [88]. This protein is closely correlated with disease activity and therapeutic efficacy in several diseases, showing to be a promising marker also in AIDs and TRAPS [89]. In recent years, adipose tissue-derived peptides, such as leptin, resistin, visfatin, and adiponectin, have also drawn interest as key players in systemic inflammation. Notably, serum leptin levels significantly correlate with TRAPS severity, while serum adiponectin levels are significantly increased in TRAPS patients with reactive amyloidosis [90]. Finally, as recently shown by Lucherini et al., serum miRNA levels will probably represent future markers of disease activity and response to therapies in TRAPS [53].

TRAPS treatment

TRAPS management is more challenging than in other monogenic AIDs because of the genetic heterogeneity giving rise to protean multiple clinical features. Treatment depends on disease activity and its main targets are to control symptoms, guarantee a good quality of life, and prevent long-term complications (such as amyloidosis) [91]. Few patients obtain symptomatic relief from non-steroidal antinflammatory drugs (NSAIDs), while colchicine and several immunomodulators such as methotrexate, cyclosporine, and thalidomide have very little efficacy [17]. Corticosteroids are useful during inflammatory attacks, but patients often require escalating doses, developing metasteroidal comorbidities over time. Furthermore, corticosteroids do not prevent amyloidosis, and relapses are frequent after withdrawal. Nevertheless, corticosteroids and NSAIDs “on demand” may be considered in patients with a mild disease. Notably, data from the Eurofever project indicated that patients carrying the low-penetrance R92Q mutation seemed to respond better to NSAIDs and colchicine versus patients with other TNFRSF1A mutations [92]. Basing on TRAPS pathogenesis, etanercept has been regarded as the primary therapeutic choice: it has shown to be effective in a subset of TRAPS patients to prevent disease flares and allow corticosteroid dose reduction [93, 94]. However, according to Bulua et al., etanercept does not completely normalize symptoms or acute-phase reactants [95]. In addition, conflicting data have been published on the efficacy of etanercept in the treatment of TRAPS-related reactive amyloidosis, with anecdotal reports describing etanercept efficacy [96] and others stating that it is unable to induce amyloidosis regression [97]. Moreover, etanercept also showed a lack or a gradually loss of efficacy over time, requiring a switch to other therapies [95, 98, 99]. Significantly, the administration of other anti-TNF agents, such as infliximab, the mouse-human chimeric monoclonal IgG1 antibody to TNF, and adalimumab, the fully humanized anti-TNF monoclonal antibody, may trigger paradoxical inflammatory attacks in TRAPS patients. Hypothetical mechanisms underlying such reactions have been suggested: (a) anti-TNF-α agents could cause apoptosis failure in peripheral blood mononuclear cells; (b) a reduced shedding infliximab-bound TNF/TNFRI from the cell surface triggers the anti-apoptotic NF-κB c-Rel subunit activation, inducing a proinflammatory response; (c) a more stable complex with the soluble TNF-α and higher avidity for the transmembrane TNF than etanercept should generate a febrile flare [100, 101, 102].

Anti-IL-1 agents are proving to be reasonable treatment options in order to prevent TRAPS relapses both in the short- and long term [92, 103]. In this regard, the recombinant IL-1 receptor antagonist anakinra has showed favorable and sustained responses, bringing about a prompt resolution of all TRAPS clinical manifestations, even the ones related to systemic amyloidosis [98, 104, 105]. However, refractoriness to anakinra in a patient carrying the T50M TNFRSF1A mutation has also been reported [106]. Recently, two reports have showed the successful treatment with the human IgG1 anti-IL-1β monoclonal antibody canakinumab [107, 108]. In line with these findings, preliminary data from a recent phase II trial carried out on 20 TRAPS patients show that canakinumab produced a remarkable clinical benefit, which was prolonged by continued administration. Disease relapses occurring at a median of 3 months after canakinumab withdrawal were usually mild or moderate, but resolved when canakinumab was resumed [109]. However, a partial loss of efficacy in a TRAPS patient who received canakinumab has recently been described: surprisingly, when alendronate was added to canakinumab, in order to treat a concomitant corticosteroid-induced osteoporosis, disease activity was promptly and fully controlled [110]. These same findings were also strikingly described in a boy with mevalonate kinase deficiency syndrome, a metabolic disorder included in the family of AIDs [111].

Recently, since IL-6 levels may be elevated in TRAPS patients [112], tocilizumab, the humanized monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6, has been used in etanercept- and anakinra-resistant TRAPS patients, achieving satisfactory results. A 52-year-old man carrying the C33Y TNFRSF1A mutation, in whom etanercept and anakinra had failed, was treated with tocilizumab for 6 months. During treatment, no attacks occurred and acute-phase reactants promptly dropped to normal values, suggesting that tocilizumab might be an alternative therapeutic option for TRAPS [113]. However longer term follow-up studies are needed to ensure tocilizumab effectiveness over time.

Upregulation of proinflammatory cytokines such as IL-1β results central to the pathogenesis of many other disorders, and close connections have also been established between inflammatory and metabolic pathways. For instance, oligomers of islet amyloid polypeptides sustain persistent IL-1β positive feedback in patients with type 2 diabetes, and many disorders of bone development and remodeling might involve a still unraveled interplay among Wnt proteins, Wnt signaling antagonists, and IL-1β. Considerable progress is expected in our understanding of the molecular links between autoinflammation and human pathology, and the extraordinary advance in the field of genetics will presumably lead to a better understanding of the intimate pathogenetic mechanisms behind TRAPS, probably helping the identification of new specific therapeutic targets which might relieve our patients’ suffering in a near future.


Conflict of interest



  1. 1.
    Touitou I, Koné-Paut I (2008) Autoinflammatory diseases. Best Pract Res Clin Rheumatol 22:811–829PubMedCrossRefGoogle Scholar
  2. 2.
    McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3:e297PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Drenth JP, van der Meer JW (2006) The inflammasome—a linebacker of innate defense. N Engl J Med 355:730–732PubMedCrossRefGoogle Scholar
  4. 4.
    Rigante D (2012) The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev 11:348–356PubMedCrossRefGoogle Scholar
  5. 5.
    Gattorno M, Federici S, Pelagatti MA, Caorsi R, Brisca G, Malattia C et al (2008) Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol 28(Suppl 1):S73–S83PubMedCrossRefGoogle Scholar
  6. 6.
    Rigante D (2009) Autoinflammatory syndromes behind the scenes of recurrent fevers in children. Med Sci Monit 15:RA179–RA187PubMedGoogle Scholar
  7. 7.
    Williamson LM, Hull D, Mehta R, Reeves WG, Robinson BH, Toghill PJ (1982) Familial Hibernian fever. Q J Med 51:469–480PubMedGoogle Scholar
  8. 8.
    McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133–144PubMedCrossRefGoogle Scholar
  9. 9.
    Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK et al (2003) Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 48:2632–2644PubMedCrossRefGoogle Scholar
  10. 10.
    Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH et al (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69:301–314PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Cantarini L, Lucherini OM, Cimaz R, Brizi MG, Galeazzi M (2010) Serosal involvement in adult-onset autoinflammatory disorders. Respiration 80:260–261PubMedCrossRefGoogle Scholar
  12. 12.
    Cantarini L, Lucherini OM, Brucato A, Barone L, Cumetti D, Iacoponi F et al (2012) Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol 101:525–531PubMedCrossRefGoogle Scholar
  13. 13.
    Cantarini L, Lucherini OM, Baldari CT, Laghi Pasini F, Galeazzi M (2010) Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol 28:405–407PubMedGoogle Scholar
  14. 14.
    Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Bellisai F, Rossi Paccani S et al (2009) Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunopathol Pharmacol 22:1051–1058PubMedGoogle Scholar
  15. 15.
    Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Laghi Pasini F, Galeazzi M (2010) Sacroileitis and pericarditis: atypical presentation of tumor necrosis factor receptor-associated periodic syndrome and response to etanercept therapy. Clin Exp Rheumatol 28:290–291PubMedGoogle Scholar
  16. 16.
    Lainka E, Neudorf U, Lohse P, Timmann C, Stojanov S, Huss K et al (2009) Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics. Rheumatology (Oxford) 48:987–991CrossRefGoogle Scholar
  17. 17.
    Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM et al (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81:349–368CrossRefGoogle Scholar
  18. 18.
    Kusuhara K, Nomura A, Nakao F, Hara T (2004) Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family. Eur J Pediatr 163:30–32PubMedCrossRefGoogle Scholar
  19. 19.
    McDermott MF, Ogunkolade BW, McDermott EM, Jones LC, Wan Y, Quane KA et al (1998) Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet 62:1446–1451PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Mulley J, Saar K, Hewitt G, Ruschendorf F, Phillips H, Colley A et al (1998) Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet 62:884–889PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Turner MD, Chaudhry A, Nedjai B (2012) Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion. Biosci Rep 32:105–112PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, Radford PM, Powell RJ, Todd I et al (2006) Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 54:2674–2687PubMedCrossRefGoogle Scholar
  23. 23.
    Cantarini L, Rigante D, Merlini G, Vitale A, Caso F, Lucherini OM et al (2013) The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum. doi:10.1016/j.semarthrit.2013.12.002 PubMedGoogle Scholar
  24. 24.
    Sarrauste de Menthiere C, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I (2003) INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 31:282–285PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Lobito AA, Gabriel TL, Medema JP, Kimberley FC (2011) Disease causing mutations in the TNF and TNFR superfamilies: focus on molecular mechanisms driving disease. Trends Mol Med 17:494–505PubMedCrossRefGoogle Scholar
  26. 26.
    Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717–1725PubMedCrossRefGoogle Scholar
  27. 27.
    Gommerman JL, Browning JL (2003) Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 3:642–655PubMedGoogle Scholar
  28. 28.
    Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd (2004) Biology of tumor necrosis factor-alpha—implications for psoriasis. Exp Dermatol 13:193–222PubMedCrossRefGoogle Scholar
  29. 29.
    Kollias G (2005) TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34:3–6PubMedCrossRefGoogle Scholar
  30. 30.
    Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6:205–217PubMedGoogle Scholar
  31. 31.
    Brennan FM, Maini RN, Feldmann M (1995) Cytokine expression in chronic inflammatory disease. Br Med Bull 51:368–384PubMedGoogle Scholar
  32. 32.
    Beutler B, Cerami A (1989) The biology of cachectin/TNF—a primary mediator of the host response. Annu Rev Immunol 7:625–655PubMedCrossRefGoogle Scholar
  33. 33.
    Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL (1992) Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 149:3881–3888PubMedGoogle Scholar
  34. 34.
    Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411–452PubMedCrossRefGoogle Scholar
  35. 35.
    Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45–65PubMedCrossRefGoogle Scholar
  36. 36.
    Kimberley FC, Lobito AA, Siegel RM, Screaton GR (2007) Falling into TRAPS—receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 9:217PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C et al (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73:431–445PubMedCrossRefGoogle Scholar
  38. 38.
    Magnotti F, Vitale A, Rigante D, Lucherini OM, Cimaz R, Muscari I et al (2013) The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. Clin Exp Rheumatol 31:141–149PubMedGoogle Scholar
  39. 39.
    Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM et al (2006) Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 108:1320–1327PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Huggins ML, Radford PM, McIntosh RS, Bainbridge SE, Dickinson P, Draper-Morgan KA et al (2004) Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum 50:2651–2659PubMedCrossRefGoogle Scholar
  41. 41.
    Kallinich T, Briese S, Roesler J, Rudolph B, Sarioglu N, Blankenstein O et al (2004) Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 31:2519–2522PubMedGoogle Scholar
  42. 42.
    Stojanov S, Dejaco C, Lohse P, Huss K, Duftner C, Belohradsky BH et al (2008) Clinical and functional characterisation of a novel TNFRSF1A c.605 T > A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 67:1292–1298PubMedCrossRefGoogle Scholar
  43. 43.
    Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM (2012) Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 12:570–580PubMedGoogle Scholar
  44. 44.
    Simon A, Park H, Maddipati R, Lobito AA, Bulua AC, Jackson AJ et al (2010) Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A 107:9801–9806PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY et al (2011) Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 208:519–533PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M (2005) Reactive oxygen species promote TNF alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120:649–661PubMedCrossRefGoogle Scholar
  47. 47.
    Dickie LJ, Aziz AM, Savic S, Lucherini OM, Cantarini L, Geiler J et al (2012) Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 71:2035–2043PubMedCrossRefGoogle Scholar
  48. 48.
    Pahl HL, Baeuerle PA (1997) The ER-overload response: activation of NF-kappa B. Trends Biochem Sci 22:63–67PubMedCrossRefGoogle Scholar
  49. 49.
    Bernales S, Papa FR, Walter P (2006) Intracellular signaling by the unfolded protein response. Annu Rev Cell Dev Biol 22:487–508PubMedCrossRefGoogle Scholar
  50. 50.
    Bachetti T, Chiesa S, Castagnola P, Bani D, Di Zanni E, Omenetti A et al (2013) Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis 72:1044–1052PubMedCrossRefGoogle Scholar
  51. 51.
    Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK (2011) MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther 13:229PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J et al (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659–666PubMedCrossRefGoogle Scholar
  53. 53.
    Lucherini OM, Obici L, Ferracin M, Fulci V, McDermott MF, Merlini G et al (2013) First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). PLoS One 8:e73443CrossRefGoogle Scholar
  54. 54.
    Rittore C, Sanchez E, Soler S, Barat-Houari M, Albers M, Obici L et al (2014) Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene. Ann Rheum Dis 73:290–297PubMedCrossRefGoogle Scholar
  55. 55.
    Cantarini L, Lucherini OM, Iacoponi F, Cimaz R, Simonini G, Rigante D et al (2010) Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders. Int J Immunopathol Pharmacol 23:1133–1141PubMedGoogle Scholar
  56. 56.
    Cantarini L, Vitale A, Lucherini OM, Muscari I, Magnotti F, Brizi G et al (2013) Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined. Reumatismo 65:55–62PubMedCrossRefGoogle Scholar
  57. 57.
    Stojanov S, McDermott MF (2005) The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 7:1–18PubMedCrossRefGoogle Scholar
  58. 58.
    Dodé C, Andre M, Bienvenu T, Hausfater P, Pecheux C, Bienvenu J et al (2002) The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 46:2181–2188PubMedCrossRefGoogle Scholar
  59. 59.
    Rigante D, Frediani B, Galeazzi M, Cantarini L (2013) From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases. Biomed Res Int 2013:485103PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Cantarini L, Lucherini OM, Cimaz R, Rigante D, Baldari CT, Laghi Pasini F et al (2012) Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. Rheumatol Int 32:4015–4018PubMedCrossRefGoogle Scholar
  61. 61.
    Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L et al (2013) The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204184 Google Scholar
  62. 62.
    Cantarini L, Lucherini OM, Cimaz R, Galeazzi M (2010) Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin Exp Rheumatol 28:802PubMedGoogle Scholar
  63. 63.
    Toro JR, Aksentijevich I, Hull K, Dean J, Kastner DL (2000) Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch Dermatol 136:1487–1494PubMedGoogle Scholar
  64. 64.
    Rigante D, Cantarini L (2011) Monogenic autoinflammatory syndromes at a dermatological level. Arch Dermatol Res 303:375–380PubMedCrossRefGoogle Scholar
  65. 65.
    Schmaltz R, Vogt T, Reichrath J (2010) Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Dermatoendocrinol 2:26–29PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Hull KM, Wong K, Wood GM, Chu WS, Kastner DL (2002) Monocytic fasciitis: a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum 46:2189–2194PubMedCrossRefGoogle Scholar
  67. 67.
    Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M et al (2013) Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. doi:10.1155/2013/513782 PubMedCentralPubMedGoogle Scholar
  68. 68.
    Haas SL, Lohse P, Schmitt WH, Hildenbrand R, Karaorman M, Singer MV et al (2006) Severe TNF receptor-associated periodic syndrome due to 2 TNFRSF1A mutations including a new F60V substitution. Gastroenterology 130:172–178PubMedCrossRefGoogle Scholar
  69. 69.
    Yao Q, Englund KA, Hayden SP, Tomecki KJ (2012) Tumor necrosis factor receptor associated periodic fever syndrome with photographic evidence of various skin disease and unusual phenotypes: case report and literature review. Semin Arthritis Rheum 41:611–617PubMedCrossRefGoogle Scholar
  70. 70.
    Minden K, Aganna E, McDermott MF, Zink A (2004) Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 63:1356–1357PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Wildemann B, Rudofsky G Jr, Kress B, Jarius S, Konig F, Schwenger V (2007) The tumor-necrosis-factor-associated periodic syndrome, the brain, and tumor-necrosis-factor-alpha antagonists. Neurology 68:1742–1744PubMedCrossRefGoogle Scholar
  72. 72.
    Obici L, Merlini G (2012) Amyloidosis in autoinflammatory syndromes. Autoimmun Rev 12:14–17PubMedCrossRefGoogle Scholar
  73. 73.
    Rigante D, Capoluongo E (2011) The plodding diagnosis of monogenic autoinflammatory diseases in childhood: from the clinical scenery to laboratory investigation. Clin Chem Lab Med 49:783–791PubMedGoogle Scholar
  74. 74.
    Pelagatti MA, Meini A, Caorsi R, Cattalini M, Federici S, Zulian F et al (2011) Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum 63:1141–1150PubMedCentralPubMedCrossRefGoogle Scholar
  75. 75.
    Ravet N, Rouaghe S, Dode C, Bienvenu J, Stirnemann J, Levy P et al (2006) Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65:1158–1162PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Cantarini L, Lucherini OM, Cimaz R, Brizi MG, Galeazzi M (2011) Autoinflammatory disorders and patients with isolated serosal involvement. Rheumatol Int 31:979–980PubMedCrossRefGoogle Scholar
  77. 77.
    Cantarini L, Imazio M, Brizi MG, Lucherini OM, Brucato A, Cimaz R et al (2013) Role of autoimmunity and autoinflammation in the pathogenesis of idiopathic recurrent pericarditis. Clin Rev Allergy Immunol 44:6–13PubMedCrossRefGoogle Scholar
  78. 78.
    Cantarini L, Lucherini OM, Vitale A, Sabadini L, Brizi MG, Frediani B et al (2013) Expanding spectrum of TNFRSF1A gene mutations among patients with idiopathic recurrent acute pericarditis. Intern Med J 43:725–727PubMedCrossRefGoogle Scholar
  79. 79.
    Cantarini L, Imazio M, Brucato A, Lucherini OM, Galeazzi M (2010) Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmun Rev 9:436–440PubMedCrossRefGoogle Scholar
  80. 80.
    Rigante D, Cantarini L, Imazio M, Lucherini OM, Sacco E, Galeazzi M et al (2011) Autoinflammatory diseases and cardiovascular manifestations. Ann Med 43:341–346PubMedCrossRefGoogle Scholar
  81. 81.
    Trost S, Rose CD (2005) Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 32:175–177PubMedGoogle Scholar
  82. 82.
    Roubille F, Cayla G, Gahide G, Mourad G, Macia JC (2009) Acute myocarditis and tumor necrosis factor receptor-associated periodic (TRAP) syndrome: first case described and discussion. Eur J Intern Med 20:e25–e26PubMedCrossRefGoogle Scholar
  83. 83.
    Chia S, Qadan M, Newton R, Ludlam CA, Fox KA, Newby DE (2003) Intra-arterial tumor necrosis factor-alpha impairs endotheliumdependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 23:695–701PubMedCrossRefGoogle Scholar
  84. 84.
    Muscari I, Iacoponi F, Cantarini L, Lucherini OM, Simonini G, Brizi MG et al (2012) The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. Autoimmun Rev 12:10–13PubMedCrossRefGoogle Scholar
  85. 85.
    Cantarini L, Iacoponi F, Lucherini OM, Obici L, Brizi MG, Cimaz R et al (2011) Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults. Int J Immunopathol Pharmacol 24:695–702PubMedGoogle Scholar
  86. 86.
    Manukyan G, Ghazaryan K, Ktsoyan Z, Khachatryan Z, Kelly D, Tatyan M et al (2010) Comparative analysis of cytokine profiles in autoinflammatory and autoimmune conditions. Cytokine 50:146–151PubMedCrossRefGoogle Scholar
  87. 87.
    Husby G, Husebekk A, Skogen B, Sletten K, Marhaug G, Magnus J et al (1988) Serum amyloid A (SAA)-the precursor of protein AA in secondary amyloidosis. Adv Exp Med Biol 243:185–192PubMedCrossRefGoogle Scholar
  88. 88.
    Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL (2001) Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 69:986–994PubMedGoogle Scholar
  89. 89.
    Cantarini L, Rigante D, Brizi MG, Lucherini OM, Sebastiani GD, Vitale A et al (2012) Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med 44:664–673PubMedCrossRefGoogle Scholar
  90. 90.
    Cantarini L, Obici L, Simonini G, Cimaz R, Bacarelli MR, Merlini G et al (2012) Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Clin Exp Rheumatol 30:S108–S114PubMedGoogle Scholar
  91. 91.
    Cantarini L, Lucherini OM, Muscari I, Frediani B, Galeazzi M, Brizi MG et al (2012) Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 12:38–43PubMedCrossRefGoogle Scholar
  92. 92.
    Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C et al (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72:678–685PubMedCrossRefGoogle Scholar
  93. 93.
    Cantarini L, Lucherini OM, Galeazzi M, Fanti F, Simonini G, Baldari CT et al (2009) Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment. Clin Exp Rheumatol 27:890–891PubMedGoogle Scholar
  94. 94.
    Cantarini L, Rigante D, Lucherini OM, Cimaz R, Laghi Pasini F, Baldari CT et al (2010) Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 23:701–707PubMedGoogle Scholar
  95. 95.
    Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR et al (2012) Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 64:908–913PubMedCrossRefGoogle Scholar
  96. 96.
    Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ (2004) Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 43:1405–1408CrossRefGoogle Scholar
  97. 97.
    Simsek I, Kaya A, Erdem H, Pay S, Yenicesu M, Dinc A (2010) No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy. J Nephrol 23:119–123PubMedGoogle Scholar
  98. 98.
    Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58:1516–1520PubMedCrossRefGoogle Scholar
  99. 99.
    Jacobelli S, Andre M, Alexandra JF, Dode C, Papo T (2007) Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 46:1211–1212CrossRefGoogle Scholar
  100. 100.
    Nedjai B, Hitman GA, Quillinan N, Coughlan RJ, Church L, McDermott MF et al (2009) Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 60:619–625PubMedCrossRefGoogle Scholar
  101. 101.
    Drewe E, Powell RJ, McDermott EM (2007) Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 46:1865–1866CrossRefGoogle Scholar
  102. 102.
    Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418–426PubMedCrossRefGoogle Scholar
  103. 103.
    Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F et al (2013) Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm 2013:939847CrossRefGoogle Scholar
  104. 104.
    Sacre K, Brihaye B, Lidove O, Papo T, Pocidalo MA, Cuisset L et al (2008) Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol 35:357–358PubMedGoogle Scholar
  105. 105.
    Obici L, Meini A, Cattalini M, Chicca S, Galliani M, Donadei S et al (2011) Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 70:1511–1512PubMedCrossRefGoogle Scholar
  106. 106.
    Quillinan N, Mannion G, Mohammad A, Coughlan R, Dickie LJ, McDermott MF et al (2011) Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 70:1692–1693PubMedCrossRefGoogle Scholar
  107. 107.
    Brizi MG, Galeazzi M, Lucherini OM, Cantarini L, Cimaz R (2012) Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med 156:907–908PubMedCrossRefGoogle Scholar
  108. 108.
    Arad U, Niv E, Caspi D, Elkayam O (2012) “TRAP” the diagnosis: a man with recurrent episodes of febrile peritonitis, not just familial Mediterranean fever. Isr Med Assoc J 14:229–231PubMedGoogle Scholar
  109. 109.
    Gattorno M, Obici L, Meini A, Tormey V, Abrams K, Davis N et al (2012) Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome [abstract]. Arthritis Rheum 64:749Google Scholar
  110. 110.
    Lopalco G, Rigante D, Vitale A, Frediani B, Iannone F, Cantarini L (2014) Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol Mar 11 - Epub ahead of printGoogle Scholar
  111. 111.
    Cantarini L, Vitale A, Magnotti F, Lucherini OM, Caso F, Frediani B et al (2013) Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis 8:196PubMedCentralPubMedCrossRefGoogle Scholar
  112. 112.
    Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA, Tighe PJ et al (2006) Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) 45:31–37CrossRefGoogle Scholar
  113. 113.
    Vaitla PM, Radford PM, Tighe PJ, Powell RJ, McDermott EM, Todd I et al (2011) Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 63:1151–1155PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2014

Authors and Affiliations

  • Donato Rigante
    • 1
  • Giuseppe Lopalco
    • 2
  • Antonio Vitale
    • 3
  • Orso Maria Lucherini
    • 3
  • Caterina De Clemente
    • 3
  • Francesco Caso
    • 3
    • 4
  • Giacomo Emmi
    • 5
  • Luisa Costa
    • 6
  • Elena Silvestri
    • 5
  • Laura Andreozzi
    • 1
  • Florenzo Iannone
    • 2
  • Mauro Galeazzi
    • 3
  • Luca Cantarini
    • 3
  1. 1.Institute of PediatricsUniversità Cattolica Sacro CuoreRomeItaly
  2. 2.Interdisciplinary Department of Medicine, Rheumatology Unit, Policlinic HospitalUniversity of BariBariItaly
  3. 3.Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit, Policlinico Le ScotteUniversity of SienaSienaItaly
  4. 4.Rheumatology Unit, Department of Medicine DIMEDUniversity of PaduaPaduaItaly
  5. 5.Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly
  6. 6.Rheumatology Unit, Department of Clinical Medicine and SurgeryUniversity Federico IINaplesItaly

Personalised recommendations